Related Experiment Video
Updated: Jun 18, 2025
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Synergistic effect of PAK and Hippo pathway inhibitor combination in NF2-deficient Schwannoma
Dorothy Benton1, Hoi Yee Chow2, Sofiia Karchugina2
1Department of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania, United States of America.
Abstract:
Neurofibromatosis type 2 is a genetic disorder that results in the formation and progressive growth of schwannomas, ependymomas, and/or meningiomas. The NF2 gene encodes the Merlin protein, which links cell cortical elements to the actin cytoskeleton and regulates a number of key enzymes including Group I p21-activated kinases (PAKs), the Hippo-pathway kinase LATS, and mTORC. While PAK1 and PAK2 directly bind Merlin and transmit proliferation and survival signals when Merlin is mutated or absent, inhibition of Group 1 PAKs alone has not proven sufficient to completely stop the growth of NF2-deficient meningiomas or schwannomas in vivo, suggesting the need for a second pathway inhibitor. As the Hippo pathway is also activated in NF2-deficient cells, several inhibitors of the Hippo pathway have recently been developed in the form of YAP-TEAD binding inhibitors. These inhibitors prevent activation of pro-proliferation and anti-apoptotic Hippo pathway effectors. In this study, we show that PAK inhibition slows cell proliferation while TEAD inhibition promotes apoptotic cell death. Finally, we demonstrate the efficacy of PAK and TEAD inhibitor combinations in several NF2-deficient Schwannoma cell lines.
Insights
Combining PAK and TEAD inhibitors shows promise for treating neurofibromatosis type 2 (NF2). This dual-action approach targets both cell proliferation and survival pathways, offering a new therapeutic strategy for NF2-related tumors.
Area of Science:
- Oncology
- Genetics
- Cell Biology
Background:
- Neurofibromatosis type 2 (NF2) is a genetic disorder characterized by schwannomas, ependymomas, and meningiomas.
- The NF2 gene encodes the Merlin protein, crucial for cytoskeletal linkage and regulation of kinases like PAKs and the Hippo pathway.
- While PAK inhibition slows tumor growth, it's insufficient alone, necessitating combination therapies.
Purpose of the Study:
- To investigate the efficacy of combined PAK and TEAD inhibitors in NF2-deficient tumors.
- To explore the synergistic effects of inhibiting both proliferation and apoptosis pathways.
Main Methods:
- Utilizing YAP-TEAD binding inhibitors to target the Hippo pathway.
- Employing PAK inhibitors to modulate cell proliferation signals.
- Testing combination therapies in NF2-deficient schwannoma cell lines.
Main Results:
- PAK inhibition demonstrated a reduction in cell proliferation.
- TEAD inhibition was found to induce apoptotic cell death.
- Combined PAK and TEAD inhibition proved effective in NF2-deficient schwannoma cell lines.
Conclusions:
- Dual inhibition of PAK and TEAD pathways presents a potent therapeutic strategy for NF2.
- Combination therapy offers a more effective approach than single-pathway inhibition for NF2-related tumors.
More Related Videos
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
